Wegovy Migraine and Ozempic Headache: GLP-1 Evidence, Mechanism, and Migraine Medication Interactions

Headache is a listed adverse reaction on both the Wegovy and Zepbound FDA labels. In the STEP-1 semaglutide trial, headache occurred in roughly 14% of the active arm versus roughly 10% on placebo^[1]. In SURMOUNT-1 tirzepatide rates ran 11–13% across the 5, 10, and 15 mg arms versus 9% on placebo^[2]. Most episodes are mild, transient, and clustered around the first few weeks of each dose escalation. The leading mechanism is not pharmacologic neurotoxicity — it is dehydration. GLP-1 receptor agonism blunts the thirst drive and nausea reduces fluid intake, so patients underdrink without feeling classically thirsty^[3]. For patients with pre-existing migraine disorder, the picture is more complex: obesity is itself a risk factor for both migraine prevalence and chronification^[4], and meaningful weight loss has been associated with fewer migraine days in randomized trials^[5]. Here is the evidence on what GLP-1 medications do to headache, what they may do to migraine, and how the common migraine medications interact with semaglutide and tirzepatide.

The honest summary

• Wegovy (semaglutide 2.4 mg) headache rate: roughly 14% in STEP-1 vs roughly 10% on placebo^[1]. Drug-attributable excess ~4 percentage points.
• Zepbound (tirzepatide) headache rate: 11% at 5 mg, 12% at 10 mg, 13% at 15 mg vs 9% placebo in SURMOUNT-1^[2].
• Onset and course: headache concentrates in the first 1–2 weeks after each dose escalation and resolves within 2–4 weeks of dose stability for most patients^[3].
• Primary mechanism: dehydration. GLP-1 receptor activity in the hypothalamus dampens both hunger and thirst signals, and nausea further reduces fluid intake. Patients underdrink without feeling thirsty.
• Obesity is a migraine risk factor. Hatami 2021 meta-analysis^[4] of observational studies found higher migraine prevalence in obese populations, and obesity is one of the few modifiable risk factors for progression from episodic to chronic migraine.
• Weight loss reduces migraine frequency in some trials. Di Lorenzo 2019 crossover^[5] and Caprio 2023 EMIKETO^[6] both showed reductions in migraine days with very-low-calorie or ketogenic diets in overweight migraine patients. Whether GLP-1-driven weight loss produces the same benefit has not been directly tested in an RCT.
• No known interaction between GLP-1 RAs and triptans, CGRP monoclonal antibodies (Aimovig, Emgality, Ajovy, Vyepti), gepants, or onabotulinumtoxinA (Botox) for migraine prevention.
• Idiopathic intracranial hypertension (IIH): Grech 2024 Eye^[8] showed exenatide lowered intracranial pressure and reduced monthly headache days in patients with active IIH — the only RCT-level signal that a GLP-1 RA may improve a specific headache disorder. This is hypothesis-generating, not a treatment indication.

Why this article exists

“Wegovy migraine,” “Ozempic headache,” and the constellation of related queries (“does Wegovy cause headaches,” “will my migraines get worse on Ozempic,” “can I take Imitrex with Wegovy”) attract roughly 1,200 monthly Google searches in the US. Our existing coverage at tirzepatide headaches and Zepbound headache frequency handles general headache as a side effect. This article is narrower and complementary: it is for the patient who already has a diagnosed migraine disorder (with or without aura, episodic or chronic) and is starting a GLP-1, and for the patient on a GLP-1 whose headaches feel migraine-like rather than generic dehydration headache.

Two clinical realities frame everything that follows. First, migraine and obesity overlap epidemiologically — obesity increases migraine risk and accelerates progression from episodic to chronic disease^[4]. Second, migraine pharmacology and GLP-1 pharmacology operate through entirely different receptor systems, so the interaction surface is small. The clinically important issues are dehydration, the topiramate overlap with Qsymia, and recognizing red-flag features that warrant neurology referral rather than another liter of water.

Headache rates on the FDA labels

Both the Wegovy and Zepbound prescribing information list headache among the most common adverse reactions. The canonical numbers come from the registration trials:

• Wegovy (semaglutide 2.4 mg) — STEP-1: headache reported in approximately 14% of the semaglutide arm versus approximately 10% of placebo across 68 weeks (Wilding 2021 NEJM^[1]). Most reports were mild or moderate.
• Zepbound (tirzepatide) — SURMOUNT-1: headache reported in 11% (5 mg), 12% (10 mg), and 13% (15 mg) versus 9% on placebo at 72 weeks (Jastreboff 2022 NEJM^[2]).

The drug-attributable excess is small — roughly 4 percentage points for both molecules. Headache is not in the same tier of clinical relevance as nausea (44% on Wegovy in STEP-1) or constipation (24%). It is, however, the single most common non-GI side effect that patients flag during titration, and it is the most common reason patients ask their prescriber for an OTC analgesic recommendation in the first weeks on therapy^[3].

The dehydration mechanism

Most GLP-1 headache is dehydration headache. The mechanism chain has four steps:

1. GLP-1 receptor activity in hypothalamic centers blunts both hunger and thirst signals. Patients underdrink without feeling classically thirsty.
2. Nausea (44% on Wegovy, 24–33% across the SURMOUNT-1 tirzepatide arms) further reduces voluntary fluid intake. A patient who feels nauseated does not reach for water.
3. When nausea progresses to vomiting (8–12% in SURMOUNT-1) or to loose stools, baseline mild dehydration becomes meaningful volume depletion. The Wharton 2022 clinical practice review^[3] emphasizes structured hydration as the first intervention for nearly every GI symptom in this population, partly because the downstream consequences (headache, lightheadedness, orthostatic symptoms, pre-renal acute kidney injury) all stem from the same volume-deficit common pathway.
4. A dehydrated patient is a primed substrate for headache. Caffeine withdrawal from reduced beverage intake compounds the effect for habitual coffee drinkers.

The practical implication is direct: most headache during titration responds to 64–80 oz (about 2–2.5 L) of actively tracked fluid per day, electrolyte replacement during vomiting or diarrhea, and acetaminophen rather than ibuprofen (NSAIDs compound the dehydration kidney-injury risk that both labels warn about). For more detail on the general mechanism, see our companion article on why tirzepatide causes headaches.

Migraine and obesity epidemiology

Migraine and obesity are linked. The Hatami 2021 systematic review and meta-analysis^[4] pooled observational data and found higher migraine prevalence in obese versus normal-weight populations. Two clinically important features of the relationship:

• Higher BMI tracks with higher attack frequency. The relationship is dose-dependent, not all-or-nothing. Obese patients are more likely to have chronic migraine (15+ headache days per month, 8+ migrainous) than episodic migraine compared with normal-weight patients.
• Obesity is a modifiable risk factor for chronification. Unlike genetics, sex, or age, weight is something that can move. The American Headache Society and the International Headache Society both list obesity among the modifiable factors that accelerate progression from episodic to chronic migraine.

Mechanism is plausibly multifactorial: adipose-derived pro-inflammatory cytokines, leptin and adiponectin dysregulation, hypothalamic dysfunction overlap with the migraine generator, and sleep apnea (a chronic-migraine accelerator) being more common in obesity. None of these is the same as saying weight loss reverses migraine one-to-one. The directionality of the relationship still warrants caution.

Could GLP-1 weight loss reduce migraine frequency?

The honest answer: plausibly yes, but no GLP-1 RCT has been designed with migraine days as a primary endpoint. The adjacent evidence is suggestive:

Di Lorenzo 2019^[5] ran a randomized double-blind crossover trial in 35 overweight migraine patients comparing a very-low-calorie ketogenic diet phase versus a very-low-calorie standard diet phase. Both arms produced weight loss; the ketogenic arm produced a larger reduction in migraine days, raising the question of whether the metabolic mechanism (ketosis) is doing some of the work in addition to the weight loss itself.

Caprio 2023 EMIKETO^[6] followed up with a parallel-group randomized trial of very-low- calorie ketogenic diet vs a hypocaloric balanced diet for high-frequency episodic migraine prevention. The ketogenic arm showed reductions in monthly migraine days and acute medication use.

Schumacher 2020 WHAM^[7] reported a post hoc analysis of a behavioral weight-loss trial in women with migraine and obesity; weight loss correlated with reductions in migraine frequency and improved secondary quality-of-life measures.

None of these tested a GLP-1. Two things make the translation uncertain. First, semaglutide and tirzepatide do not reliably induce nutritional ketosis — the weight loss is driven by reduced caloric intake, not by carbohydrate restriction. If ketosis is doing meaningful work in the Di Lorenzo and Caprio trials independent of weight loss, GLP-1 patients may not capture the full effect. Second, none of these trials measured the lag between weight-loss onset and migraine improvement, and anecdotally many patients report headache increasein the first few weeks on a GLP-1 (the dehydration window) followed by improvement only later. A patient with chronic migraine starting Wegovy should expect potential worsening for the first 4–8 weeks and only see a possible improvement signal — if one materializes for them — over several months of sustained weight loss.

Topiramate, Qsymia, and the GLP-1 overlap

Topiramate (Topamax, generic) is one of the most commonly prescribed migraine-prevention medications. It is also a component of the FDA-approved weight-loss combination Qsymia (phentermine plus topiramate extended-release). Several patient populations land in clinically relevant overlap territory:

• The migraine patient already on topiramate who starts a GLP-1. No pharmacokinetic interaction is described between topiramate and semaglutide or tirzepatide. Topiramate is renally cleared, semaglutide and tirzepatide are not metabolized by CYP enzymes in any way that would shift topiramate levels. Practical caveat: topiramate independently suppresses appetite and is associated with weight loss as a side effect. Stacking topiramate on a GLP-1 will not be additive in a straightforward way and may amplify the appetite-suppression burden enough that patients underdrink and underconsume protein. The prescriber should know about both medications.
• The patient switching from Qsymia to Wegovy or Zepbound. Discontinuing Qsymia removes both phentermine (sympathomimetic) and topiramate (CNS depressant, mood and cognitive effects). Stopping topiramate abruptly is generally safe at low doses but can rarely precipitate seizures at higher doses; the prescribing clinician should manage the taper. Headache can worsen briefly during the topiramate taper if topiramate was meaningfully suppressing migraine frequency.
• Kidney stone risk. Topiramate is a weak carbonic anhydrase inhibitor and increases the risk of calcium phosphate kidney stones. GLP-1 dehydration during titration compounds the stone risk. Patients on both need to be aggressive about hydration and may need a stone- prevention work-up if they have a personal or family history.

Acute migraine medications — triptans and gepants

The acute (abortive) migraine medication classes a Wegovy or Zepbound patient is most likely to be using:

• Triptans (sumatriptan/Imitrex, rizatriptan/Maxalt, eletriptan/Relpax, zolmitriptan/Zomig, naratriptan/Amerge, almotriptan/Axert, frovatriptan/Frova). 5-HT1B/1D receptor agonists. No known pharmacokinetic interaction with semaglutide or tirzepatide. The clinically relevant interaction is indirect: the slower gastric emptying produced by a GLP-1 can delay absorption of oral triptan tablets. If a patient is relying on a fast onset (e.g., rizatriptan ODT taken at the first sign of aura), nasal-spray or subcutaneous formulations (sumatriptan nasal, sumatriptan injection, zolmitriptan nasal) bypass the gut and are not affected.
• Gepants (rimegepant/Nurtec, ubrogepant/ Ubrelvy, zavegepant/Zavzpret). CGRP receptor antagonists. No known pharmacokinetic interaction with GLP-1 RAs. Same oral absorption caveat as triptans — zavegepant is intranasal and bypasses the gut.
• NSAIDs (ibuprofen, naproxen, diclofenac, ketorolac) are often used as first-line abortive treatment. Both Wegovy and Zepbound labels warn that dehydration during titration can precipitate acute kidney injury, and NSAIDs are explicitly named as a compounding risk. For acute migraine on a GLP-1, acetaminophen is the safer OTC option when it works; an occasional NSAID dose for an established migraine in an adequately hydrated patient is reasonable, but standing daily NSAID use during GLP-1 titration is the worst combination.

Preventive migraine medications

• CGRP monoclonal antibodies — erenumab (Aimovig), galcanezumab (Emgality), fremanezumab (Ajovy), eptinezumab (Vyepti). Subcutaneous or intravenous biologics. No known interaction with semaglutide or tirzepatide. Both classes are subcutaneous injections; patients should rotate sites and not stack injections in the same anatomical region on the same day.
• OnabotulinumtoxinA (Botox) for chronic migraine is administered as a series of head and neck injections every 12 weeks. No interaction with GLP-1 RAs.
• Beta blockers (propranolol, metoprolol, atenolol) are common migraine preventives. They lower heart rate; GLP-1 RAs modestly raise heart rate (semaglutide ~2–4 bpm in STEP-1 active arm vs placebo). The net effect is typically clinically unimportant but worth flagging for the prescriber.
• Antidepressants used for migraine prevention (amitriptyline, nortriptyline, venlafaxine). No pharmacokinetic GLP-1 interaction. Amitriptyline can slow GI motility, which on top of GLP-1-induced slowing can worsen constipation; an osmotic laxative regimen may be needed.
• Topiramate and divalproex as covered above; both are appetite-active and the appetite- suppression stack should be flagged for the prescriber.

Hormonal migraine, perimenopause, and the GLP-1 patient

Women with menstrual or perimenopausal migraine starting a GLP-1 are in a complicated category. Three considerations worth flagging to the prescriber:

• Estrogen withdrawal triggers migraine without aura. Perimenopausal estrogen fluctuation is a known migraine accelerator. The weight loss a GLP-1 produces does not change this; the underlying hormonal rhythm continues.
• Combined oral contraceptives are contraindicated in migraine with aura because of stroke risk. A perimenopausal patient on a GLP-1 who develops new aura symptoms should pause and get a neurology evaluation; this is not a routine titration symptom.
• Hormone therapy adjustments may be needed. Hormone therapy used for perimenopausal symptom relief is not contraindicated with GLP-1 RAs, but the combination should be co-managed by the prescribing gynecologist or endocrinologist along with the GLP-1 prescriber.

Idiopathic intracranial hypertension (IIH)

IIH (formerly “pseudotumor cerebri”) is a separate headache disorder — raised intracranial pressure without an identifiable cause, predominantly in women of childbearing age with obesity, presenting with daily holocranial headache, pulsatile tinnitus, transient visual obscurations, and papilledema on examination. Weight loss is one of the cornerstone treatments.

Grech 2024 Eye^[8] is the most relevant GLP-1 paper. The parent trial randomized active IIH patients to exenatide (twice-daily GLP-1 RA) versus placebo; the exenatide arm showed reductions in intracranial pressure (the primary endpoint of the parent study) and in monthly headache days. The mechanism is thought to be a direct effect of GLP-1 receptor activity on choroid plexus CSF production, separate from the weight-loss effect. This is the only published RCT signal that a GLP-1 medication may have a disease-specific benefit for a headache disorder. It is hypothesis-generating, not a treatment indication: exenatide is not FDA-approved for IIH, and the data on semaglutide and tirzepatide specifically for IIH are still emerging.

When migraine or headache on a GLP-1 needs neurology work-up

Most headache during GLP-1 titration responds to hydration. The clinical scenarios that should not be managed as dehydration headache:

• Thunderclap headache — sudden, severe, “worst headache of life,” peaking in under a minute. Emergency department evaluation for subarachnoid hemorrhage. Not a GLP-1 side effect.
• New onset of focal neurological symptoms — facial droop, arm weakness, speech difficulty, vision loss, or aura in a patient who has never had aura before. Stroke workup. Not a GLP-1 titration symptom.
• Headache with postural component — worse on standing, better on lying down (low-pressure headache pattern) or worse on lying down and on straining/coughing (high-pressure / IIH pattern). Either warrants neurology evaluation; the high-pressure pattern with visual obscurations and pulsatile tinnitus is a red flag for IIH.
• Sudden change in established migraine pattern — new aura, new location, dramatic frequency increase beyond the first titration weeks, change in character. Not a routine GLP-1 effect.
• Headache with fever and stiff neck— meningitis work-up.
• Headache persisting beyond 4–6 weeks at a stable GLP-1 dose in a well-hydrated patient who is not vomiting. The dehydration mechanism does not explain persistent headache at dose stability; other causes (medication overuse headache, cervicogenic headache, transformed migraine) should be considered.

Patient action plan

1. Hydrate aggressively. 64–80 oz (~2–2.5 L) of fluid daily, actively tracked, not waiting on thirst. Add an electrolyte mix on days with nausea, vomiting, or diarrhea. This single intervention resolves the majority of GLP-1 titration headache.
2. Acetaminophen over NSAIDs for routine headache during titration. Reserve NSAIDs for established migraine in an adequately hydrated patient.
3. Keep the migraine prevention regimen running. If you are on topiramate, propranolol, a CGRP biologic, or Botox, do not stop it because of a new GLP-1. Coordinate any changes with your neurologist.
4. Switch oral triptans to nasal or subcutaneous if absorption feels delayed. Sumatriptan nasal spray or subcutaneous injection bypasses the GLP-1-slowed gut.
5. Track headache days and triggers for the first 8–12 weeks on a GLP-1. If headache is worsening at a stable dose, escalate to the prescriber and consider neurology referral.
6. Get neurology evaluation for any of the red-flag scenarios above. Do not assume new neurological symptoms are GLP-1 side effects.

How GLP-1 headache rates compare to the magnitude of weight loss

The reason this comparison matters: headache is a real but modest side effect, while the weight-loss magnitude is substantial. For a patient with obesity and migraine, the clinical question is whether headache during titration is bad enough to outweigh the long-term migraine benefit that sustained weight loss may produce (and the cardiovascular and metabolic benefits independent of migraine). For most patients with a meaningful migraine history, the answer is no — titration headache is short-lived and manageable.

Bottom line

• Wegovy and Zepbound both list headache as a common adverse reaction at ~14% (Wegovy) and 11–13% (Zepbound) versus ~10% and 9% placebo respectively.
• The mechanism is mostly dehydration, not direct neurotoxicity. Hydration and acetaminophen resolve most cases.
• Obesity is a migraine risk factor, and weight loss has been associated with fewer migraine days in non-GLP-1 trials. Whether GLP-1-driven weight loss produces the same benefit is plausible but not yet demonstrated in a dedicated RCT.
• No known pharmacokinetic interaction between GLP-1 RAs and triptans, gepants, CGRP biologics, Botox, or standard migraine preventives. The clinically important overlap is topiramate (Qsymia component).
• IIH is a special case with an RCT signal (Grech 2024) that exenatide lowers intracranial pressure and reduces headache days — promising but not a treatment indication.
• Red flags (thunderclap, focal neurological deficit, postural headache with vision changes, new aura, fever and stiff neck, or persistent headache at stable dose) should not be managed as dehydration. Get neurology evaluation.

Related research and tools

• Why does tirzepatide cause headaches? — the deep-dive on tirzepatide-specific headache mechanism, FDA label rates, and the dehydration chain
• Does Zepbound cause headaches? Frequency, mechanism, and relief — trial-by-trial Zepbound headache rates across SURMOUNT-1, SURMOUNT-4, SURMOUNT-OSA, and SUMMIT
• Does Mounjaro cause headaches? — the T2D-population headache profile, including the hypoglycemia mechanism in combination therapy
• GLP-1 side effect Q&A — the broader patient-question hub covering 17 of the most-searched GLP-1 symptom queries
• GLP-1 side effect timeline — the interactive timeline showing when headache and other side effects peak and resolve across the titration schedule
• What to eat on a GLP-1: the protein-first guide — the meal pattern that minimizes nausea and downstream dehydration
• Semaglutide drug page — the full Wegovy and Ozempic clinical profile
• Tirzepatide drug page — the full Zepbound and Mounjaro clinical profile

Important disclaimer. This article is educational and does not constitute medical advice. The information here is not a substitute for evaluation by a treating physician or neurologist. Patients with diagnosed migraine disorder starting a GLP-1 should coordinate with both the prescribing clinician and their neurologist before adjusting any migraine medication. Any sudden, severe, or new-onset neurological symptoms should be evaluated in person, not online. Red-flag features (thunderclap onset, focal deficits, vision loss, fever with stiff neck, or aura in a patient without prior aura) warrant emergency or urgent neurology evaluation. PMIDs were independently verified against the PubMed E-utilities API on 2026-05-28. FDA label rates were taken from the Wegovy and Zepbound prescribing information on DailyMed.

Last verified: 2026-05-28. Next review: every 12 months, or sooner if a dedicated GLP-1 RCT with migraine days as a primary endpoint is published.